Imatinib Mesylate is a tyrosine kinase inhibitor that is used orally in the treatment of skin cancer. Since it is a hydrophilic drug, it is a challenge to design a carrier to incorporate this drug with suitable encapsulation efficiency. Reverse micelles having inner hydrophilic and outer hydrophobic core was prepared using lecithin and isopropyl myristate to encapsulate imatinb mesylate. The encapsulation performance of reverse micelles packed with imatinib mesylate was found to be 47%. The composition of reverse micelles has an impact on the size and the index of polydispersity. To avoid systemic side effects associated with oral administration, topical treatment using organogel may be used. Using pluronic F 127 as hydrophilic polymer, reverse micelle containing imatinib mesylate was converted into organogel. The formulated organogel consisted of 30% w/v of reverse micelles containing imatinib mesylate and 70% of the pluronic F127. The formulated organogel was found to have suitable physical properties. In vitro diffusion studies show that drug was released up to 46.02% over a period of 8 hrs.
Cite this article:
R. Nithya, Binita Kumari. Development and Characterization of Reverse Micelle based Pluronic Lecithin Organogel containing Imatinib Mesylate. Research J. Pharm. and Tech 2021; 14(3):1209-1214. doi: 10.5958/0974-360X.2021.00215.8
R. Nithya, Binita Kumari. Development and Characterization of Reverse Micelle based Pluronic Lecithin Organogel containing Imatinib Mesylate. Research J. Pharm. and Tech 2021; 14(3):1209-1214. doi: 10.5958/0974-360X.2021.00215.8 Available on: https://rjptonline.org/AbstractView.aspx?PID=2021-14-3-3
1. Rele., et al. "Derivative UV Spectrophotometric Method for Validation of Imatinib mesylate in Bulk and Pharmaceutical Dosage Form." Asian Journal of Research in Chemistry. 2019; 12(5): 253-257.
2. Guilhot, et al. Indications for imatinib mesylate therapy and clinical management. The Oncologist. 2004; 9(3): 271-281.
3. Wei., et al. Efficacy evaluation of imatinib for the treatment of melanoma: evidence from a retrospective study. Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics. 2019; 27(4): 495-501.
4. Navarrete-Dechent, et al. Imatinib treatment for locally advanced or metastatic dermatofibrosarcoma protuberans: a systematic review. JAMA Dermatology. 2019; 155(3): 361-369.
5. Le Garrec., et al. Micelles in anticancer drug delivery. American Journal of Drug Delivery. 2004; 2(1): 15-42.
6. Senthil., et al. Formulation and evaluation of imatinib mesylate microspheres by chemical crosslinking method. Research Journal of Pharmacy and Technology. 2012; 5(7): 934-937.
7. Trivedi., et al. Nanomicellar formulations for sustained drug delivery: strategies and underlying principles. Nanomedicine. 2010; 5(3): 485-505.
8. Lone., et al. Concept of Reverse Micelle Method For the Synthesis of Nano-Structured Materials. Current Nanoscience. 2019; 15(2): 129-136.
9. Vrignaud., et al. Reverse micelle-loaded lipid nanocarriers: a novel drug delivery system for the sustained release of doxorubicin hydrochloride. European Journal of Pharmaceutics and Biopharmaceutics. 2011; 79(1): 197-204.
10. Vrignaud., et al. Design, optimization and in vitro evaluation of reverse micelle-loaded lipid nanocarriers containing erlotinib hydrochloride. International Journal of Pharmaceutics. 2012; 436 (1-2): 194-200.
11. Agrawal., et al. Preparation and characterization of reverse micelle based organogels of piroxicam. Die Pharmazie-An International Journal of Pharmaceutical Sciences. 2004; 59(3): 191-193.
12. Jain., et al. Characterization of Ocular Delivery of Reverse Micelles Bearing Insulin. Research Journal of Pharmacy and Technology. 2008; 1(4): 370-373.
13. Esposito., et al. Organogels, promising drug delivery systems: an update of state-of-the-art and recent applications. Journal of Controlled Release. 2018; 271: 1-20.
14. Almeida., et al. Pluronic® F-127 and Pluronic Lecithin Organogel (PLO): main features and their applications in topical and transdermal administration of drugs. Journal of Pharmacy and Pharmaceutical Sciences. 2012; 15(4): 592-605.
15. Saha., et al. Pluronic lecithin organogels: An effective topical and transdermal drug delivery system. Int J Pharm Sci Res. 2018; 11: 4540-4550.
16. Fu., et al. Physicochemical Characterization of Lecithin/Isopropyl Myristate Reverse Micelles. Chemistry Select. 2017; 2(24): 7439-7444.
17. Jhawat., et al. Formulation and evaluation of novel controlled release of topical pluronic lecithin organogel of mefenamic acid. Drug delivery. 2016; 23(9): 3573-3581.
18. Mady., et al. Formulation and clinical evaluation of silymarin pluronic-lecithin organogels for treatment of atopic dermatitis. Drug Design, Development and Therapy. 2016; (10): 1101.
19. Esposito., et al. Organogels, promising drug delivery systems: an update of state-of-the-art and recent applications. Journal of Controlled Release. 2018; 271: 1-20.
20. Kumar., et al. Lecithin organogels as a potential phospholipid-structured system for topical drug delivery: a review. AAPS Pharmscitech. 2005; 6(2): E298-E310.